Navigation Links
NIH Funds Synedgen to Develop a New Drug to Improve Airway Clearance
Date:9/27/2013

to tackle biofilms and sputum, reducing their cohesion and viscosity to allow the patient to clear them both. Our preliminary data demonstrates that our polymeric drug both reduces the viscosity of CF sputum and improves sputum mobility in vitro, and separately loosens biofilms,” stated Synedgen President Shenda Baker. “We hypothesize the drug will have significant synergistic activity with traditional antibiotics, and are eager to explore the magnitude and duration of these effects in mucus, biofilms, and in combination.”

In other studies of pathogenic infection and mucosal surface damage, this new drug has been shown to reduce inflammation at the surface. Since cystic fibrosis is a disease severely affected by airway inflammation, future studies will also examine the drug’s potential additional role in mitigating pulmonary inflammation.

“The preliminary data are extremely exciting,” stated Dr. Steven Rowe, “and could provide a new avenue to address mucus stasis in CF lung disease, potentially improving lung health.”

Preliminary results from these studies will be presented in October at the 27th Annual North American Cystic Fibrosis Conference. Synedgen hopes its new drug will make the sputum flow more freely, break up pathogenic biofilms and also enhance activity of standard antibiotics, providing a new and highly effective pulmonary treatment to help CF patients breathe more easily and combat lung infections.

Research reported in this press release was supported by the National Heart Lung and Blood Institute of the National Institutes of Health under award number 1R43HL118867. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

About Synedgen
Synedgen Inc. is an innovative biopharmaceutical company focused on developing novel therapies and products through its proprietary biomaterials technology platform. Product develop
'/>"/>

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Foundation for Angelman Syndrome Therapeutics (FAST) Funds Human Clinical Trial
2. QB3-Industry Biotech Startup Partnership Funds Two Projects
3. German Academic Exchange Service funds international project on spintronics
4. NSBRI Funds Cerebrotech to Accelerate Development of Brain Monitoring Device
5. Express Diagnostics to Raise Funds for American Cancer Society During Blue Earth’s Giant Days Parade
6. Kitware Receives Funds from U.S. Air Force Research Lab to Extend the Bender Toolkit for Anatomical Model Repositioning
7. Synedgen’s Synoplex® Receives FDA Indexing for Use in the Treatment of Chronic Wounds in Pachyderms
8. Synedgen Announces Issuance of Patent to Optimize Animal Health
9. Synedgen Announces Effective Treatment Against Bacterial Biofilms in Minor Animal Species
10. Scarred for Life? Synedgen Hopes Not
11. Synedgen's Synoplex® is Headed to the Lewa Wildlife Conservancy in Kenya
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2015)... Atlanta, GA (PRWEB) May 06, 2015 ... solutions based on the products of cells grown ... on its 105F immunomodulatory treatment candidate for melanoma ... Annual Meeting, taking place May 6-9, 2015 in ... hypoxia-induced multipotent cells produce a soluble material with ...
(Date:5/6/2015)... (PRWEB) May 06, 2015 The ... and growth strategy for the specialty pharmacy industry, will ... the 2015 Armada Specialty Pharmacy Summit. The Summit will ... in Las Vegas and is the largest annual gathering ... be in attendance, from pharmacy providers, pharma/biotech manufacturers, and ...
(Date:5/5/2015)... , May 5, 2015  Blueprint Medicines ... of its initial public offering of 9,367,708 shares ... of $18.00 per share, including shares of common ... underwriters of their option to purchase additional shares. ... to Blueprint Medicines were approximately $168.6 million, before underwriting ...
(Date:5/5/2015)... May 5, 2015 Roka Bioscience, Inc. (NASDAQ: ... testing solutions for the detection of foodborne pathogens,  today announced ... Bank of America Merrill Lynch 2015 Health Care Conference on ... at Encore at the Wynn, Las Vegas NV. ... presentation will be available through the investor relations section of ...
Breaking Biology Technology:Novel Immunomodulatory Treatment Induces Apoptosis in Melanoma 2The Remedy Group presenting at the 2015 Armada Specialty Pharmacy Summit: The Pitfalls to Growth and Maintaining the Patient Experience 2Blueprint Medicines Announces Closing of Initial Public Offering 2
... Corp. (TSX: HBP / Frankfurt: WKN 918864), ... Corp.,announces that at the Company,s Annual General Meeting ... the resolutions presented by,management, appointing KPMG LLP as ... Kay, Slawomir Majewski, and Gordon Lickrish as,directors, and ...
... Jan. 30 MiddleBrook,Pharmaceuticals, Inc. (Nasdaq: MBRK ... novel anti-infective products, today,announced that it has closed ... warrants, resulting in the receipt of $21 million ... the proceeds from the financing to support,the manufacture ...
... Jan. 30 /Xinhua-PRNewswire-FirstCall/ --,Kiwa Bio-Tech Products Group Corporation ... bio-enhanced feed products sold during the fourth,quarter of ... and increased,25% over the same period in the ... ("Kiwa Tianjin") is a joint-venture of Kiwa,and Tianjin ...
Cached Biology Technology:Helix BioPharma shareholders vote in favour of management 2MiddleBrook Pharmaceuticals Closes Private Placement of Common Equity Raising $21 Million 2MiddleBrook Pharmaceuticals Closes Private Placement of Common Equity Raising $21 Million 3Kiwa Bio-Tech Animal Feed Volume Increased 25% in Fourth Quarter of 2007 2
(Date:4/8/2015)...  Infinisource, a leading provider of SaaS-based Human Capital ... leading supplier of biometric identification and security solutions, ... advanced biometrically-enabled time clock, the companies announced today. ... setting a bold, new standard for the collection ... and mid-size employer. When connected to the iSolved ...
(Date:4/2/2015)... April 2, 2015 According to ... attributed to somewhat higher than 125 MSEK. This exceeds ... report 2014 that revenues for Q1 2015 would be ... reported for Q4 2014. The operating result for the ... The complete interim report will as previously communicated be ...
(Date:3/31/2015)... 2015  Elephant Talk Communications Corp. (NYSE MKT: ETAK) ... Software Defined Network Architecture (ET Software DNA® 2.0) platforms ... approximately $20.4 million for the year ended December 31, ... the year ended December 31, 2013. ... completed its multi-year transition away from its legacy landline ...
Breaking Biology News(10 mins):iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3Fingerprint Cards Revises Revenues for Q1 2015 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 3Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 5Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 6
... -- Rice University scientists have unveiled a revolutionary new ... into steam. The new "solar steam" method from Rice,s ... even produce steam from icy cold water. Details ... in ACS Nano . The technology has an ...
... after Hurricane Sandy hit, NJIT Professor Michel Boufadel was awarded ... of the storm on the New Jersey shoreline. The ... a team of eight researchers to the beaches of Raritan ... students is still fanning out over the shoreline and ...
... getting, when they select females for mating, according to a ... Wisconsin-Milwaukee in the US. His work, which is one of ... mating behaviors in a nocturnal anuran (frog or toad), is ... . Animals display a number of courtship behaviors and ...
Cached Biology News:Rice unveils super-efficient solar-energy technology 2Rice unveils super-efficient solar-energy technology 3NJIT civil engineer receives NSF grant to study storm's impact on Jersey Shore 2Vision stimulates courtship calls in the grey tree frog 2
... Cultures (ECACC) in conjunction with the Univeristy ... England, Bristol, UK, have produced standardised cell ... oestrogen and progresterone receptor assays. The slides ... fixed, breast cancer cell lines; MDA-MD-361, T47D, ...
kismet (dK-20)...
... potent TURBO DNase (patent pending) in the TURBO ... DNA removal capabilities. TURBO DNase is a recombinant, ... more efficient than wild type DNase I in ... DNase binds DNA substrates 6-fold more tightly than ...
...
Biology Products: